Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II TAR-0520 gel for prevention of EGFR inhibitor-induced folliculitis
ISRCTN24863668Phase 2Recruiting
- Sponsor
- Tarian Pharma
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in folliculitis comparing TAR-0520 gel with Vehicle placebo gel (2 arms). Primary endpoint: Safety profile of TAR-0520 gel. Started Jan 2025; status: recruiting.
02
Drugs
brimonidine
03
Conditions
folliculitis
Beyond the preview
Go deeper on ISRCTN24863668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN24863668.